Friday, January 27, 2023
Home Covid-19 Pfizer files for U.S. authorization of its pill to treat COVID-19

Pfizer files for U.S. authorization of its pill to treat COVID-19

Pfizer Inc said on Tuesday it is seeking U.S. authorization of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

Pfizer said it completed submission of its application for emergency use authorization (EUA) of the drug, Paxlovid, with the U.S. Food and Drug Administration, including data from the drugmaker’s clinical trial.

The oral drug could be promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent COVID-19 hopitalizations and deaths. It could also become a important tool in countries and areas with limited access to vaccines or low vaccination rates.

Read more:
New Pfizer COVID-19 pill reduces hospital, death risk by 90%, company says

Story continues below advertisement

It is not immediately clear when U.S. regulators will rule on Pfizer’s application. Merck & Co Inc and Ridgeback Biotherapeutics, which are developing a competing pill, molnupiravir, completed their EUA submission on Oct. 11.

A panel of outside advisers to the FDA will meet to consider that application on Nov. 30, and it is expected to be available this year.

“We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the U.S. FDA on its review of our application, along with other regulatory agencies around the world,” Pfizer Chief Executive Albert Bourla said in a news release.

The New York-based drugmaker said it has begun the process of seeking authorization in several countries including the United Kingdom, Australia, New Zealand and South Korea, and plans further international submissions.

Read more:
Pfizer to allow other companies to make its COVID-19 pill

Pfizer said earlier on Tuesday it will allow generic manufacturers to supply its COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).

© 2021 Reuters

Most Popular

Nursing shortage in Winnipeg may give perps ‘free pass’ after sex assault: women’s health worker

The executive director of the Women’s Health Clinic says she’s at a loss for words after learning victims of sexual assault are being turned...

Rent report says Central Okanagan has 4th highest rent rates in nation

Finding a place to rent in the Central Okanagan isn’t just hard, it’s also expensive. But none of this is news to those who rent...

Past U.S. presidents, VPs dating back to Reagan asked to check again for classified docs

The National Archives has asked former U.S. presidents and vice presidents to recheck their personal records for any classified documents following the news that President...

New Regina homeless winter shelter set to open on Monday, Jan. 30

On Monday, Jan. 30, Regina’s newest temporary homeless shelter will officially open. The 40-space temporary shelter will open its doors downtown at the old YMCA...